

Filed On Behalf Of:
Novartis Pharmaceuticals Corporation

By:
Nicholas N. Kallas
NKallas@fchs.com
ZortressAfinitorIPR@fchs.com
(212) 218-2100

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

BRECKENRIDGE PHARMACEUTICAL, INC.,

Petitioner,

v.

NOVARTIS PHARMACEUTICALS CORPORATION,

Patent Owner.

Case IPR2017-01592

Patent No. 8,410,131

**PATENT OWNER'S NOTICE OF DEPOSITION OF
ALLAN J. PANTUCK, M.D.**

Pursuant to 37 C.F.R. § 42.53, Patent Owner Novartis Pharmaceuticals Corporation, by and through its attorneys, will conduct cross-examination by deposition of Allan J. Pantuck. The deposition will take place starting at 9:00 am PT on March 13, 2018 and continuing until completed, at Clark Urology Center – Westwood, 200 UCLA Medical Plaza, Suite 140, Los Angeles, CA 90095. In accordance with 37 C.F.R. § 42.53(d)(1), the parties have conferred and have agreed upon this date and location for Dr. Pantuck’s deposition.

The cross-examination will be taken before a Notary Public or other officer authorized by law to administer oaths. It will be recorded by stenographic, audio and/or audiovisual means.

Dated: February 28, 2018

Respectfully submitted,

/ Nicholas N. Kallas /
Nicholas N. Kallas
Registration No. 31,530
Lead Counsel for Patent Owner
FITZPATRICK, CELLA, HARPER
& SCINTO
1290 Avenue of the Americas
New York, NY 10104-3800
Tel. 212-218-2100

CERTIFICATE OF SERVICE

I certify that a copy of the foregoing PATENT OWNER'S NOTICE OF DEPOSITION OF ALLAN J. PANTUCK, M.D. was served on February 28, 2018 by causing it to be sent by email to counsel for Petitioner at the following email addresses:

Daniel R. Evans (devans@merchantgould.com)

Jeffrey D. Blake (jblake@merchantgould.com)

Melissa M. Hayworth (mhayworth@merchantgould.com)

Dated: February 28, 2018

/ Nicholas N. Kallas /
Nicholas N. Kallas
Registration No. 31,530
Lead Counsel for Patent Owner
FITZPATRICK, CELLA, HARPER
& SCINTO
1290 Avenue of the Americas
New York, NY 10104-3800
Tel. 212-218-2100